Cronos Group Inc (TSE:CRON) has been given an average rating of “Hold” by the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is C$22.63.
Several research firms have recently weighed in on CRON. CIBC lowered their price target on Cronos Group from C$30.00 to C$25.00 in a report on Friday, May 10th. Canaccord Genuity raised Cronos Group from a “sell” rating to a “hold” rating and increased their price target for the company from C$16.00 to C$17.00 in a report on Friday, August 9th. Jefferies Financial Group lowered their price target on Cronos Group from C$17.00 to C$15.00 in a report on Friday, May 3rd. Bank of America raised Cronos Group from an “underperform” rating to a “buy” rating and increased their price target for the company from C$17.00 to C$27.00 in a report on Wednesday, June 5th. Finally, Cormark lowered their price target on Cronos Group from C$25.00 to C$20.00 in a report on Friday, May 10th.
CRON stock opened at C$15.11 on Tuesday. The stock’s 50 day simple moving average is C$18.44 and its 200 day simple moving average is C$22.49. The stock has a market capitalization of $5.08 billion and a PE ratio of 21.25. The company has a current ratio of 1.68, a quick ratio of 1.64 and a debt-to-equity ratio of 0.29. Cronos Group has a 12-month low of C$8.47 and a 12-month high of C$32.95.
Cronos Group Inc, formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations ?MMPR?. The firm typically invests in companies based in Canada.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.